Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 5/20 | 0.47 |
| ▸ | FLT3 | P36888 | 2/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 13/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 12/20 | 0.42 |
| ▸ | CDK2 | P24941 | 12/20 | 0.42 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2911665 | 0.93 | CDK1 (0.47) | CDK1FLT3PDGFRACCNE1CDK2 | |
| SCHEMBL2913634 | 0.88 | CCNE1 (0.54) | CDK1FLT3PDGFRACCNE1CDK2 | |
| SCHEMBL2912622 | 0.88 | FLT3 (0.50) | CDK1FLT3PDGFRACCNE1CDK2 | |
| SCHEMBL2912961 | 0.88 | CDK1 (0.44) | CDK1FLT3PDGFRACCNE1CDK2 | |
| SCHEMBL2913588 | 0.88 | CDK1 (0.51) | CDK1FLT3PDGFRACCNE1CDK2 | |
| SCHEMBL2911932 | 0.87 | CDK1 (0.62) | CDK1PDGFRACCNE1CDK2PRKCA | |
| SCHEMBL2911647 | 0.87 | CDK1 (0.49) | CDK1FLT3PDGFRACCNE1CDK2 | |
| SCHEMBL2937905 | 0.86 | CLK1 (0.48) | CDK1CCNE1CDK2PRKCA | |
| SCHEMBL2911410 | 0.86 | CDK1 (0.44) | CDK1FLT3PDGFRACCNE1CDK2 | |
| SCHEMBL2913424 | 0.86 | CDK2 (0.47) | CDK1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1348707-B1 | Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy | USTAV EX BOTAN AV CR V V I I O (CZ) | 2010-08-25 | — | — | EP | disclosed |
| US-7745450-B2 | Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy | INSTITUTE OF EXPERIMENTAL BOTANY (CZ) | 2010-06-29 | — | — | US | disclosed |
| US-20050080097-A1 | Pyrazolo[4,3-D]pyrimidines, processes for their preparation and methods for therapy | USTAV EXPERIMENTALNI BOTANIKY AV CR (INSTITUTE OF EXPERIMENTAL BOTANY ACADEMY OF | 2005-04-14 | — | — | US | disclosed |
| EP-1348707-A1 | Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy | Ustav Experimentalni Botaniky AV CR (Institute of Experimental Botany Academy of Sciences of the Czech Republic) (CZ) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080097-A1 | Pyrazolo[4,3-D]pyrimidines, processes for their preparation and methods for therapy | CBR3, DHFR, AKR1C3 | CDK1 1081/4885FLT3 179/4885PDGFRA 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.